| Autor: |
Souza BNRF; Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil., Ribeiro ERFR; Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil., da Silva de Barros AO; Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil., Pijeira MSO; Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil., Kenup-Hernandes HO; Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil., Ricci-Junior E; DEFARMED Laboratory, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-900, Brazil., Diniz Filho JFS; Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil., Dos Santos CC; Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil., Alencar LMR; Laboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, São Luís 65080-805, Brazil., Attia MF; Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Gemini-Piperni S; Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil., Santos-Oliveira R; Argonauta Nuclear Reactor Center, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-906, Brazil.; Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Zona Oeste State University, Rio de Janeiro 23070-200, Brazil. |
| Abstrakt: |
Alpha and beta particulate radiation are used for non-treated neoplasia, due to their ability to reach and remain in tumor sites. Radium-223 ( 223 Ra), an alpha emitter, promotes localized cytotoxic effects, while radioactive gold ( 198 Au), beta-type energy, reduces radiation in the surrounding tissues. Nanotechnology, including several radioactive nanoparticles, can be safely and effectively used in cancer treatment. In this context, this study aims to analyze the antitumoral effects of [ 223 Ra]Ra nanomicelles co-loaded with radioactive gold nanoparticles ([ 198 Au]AuNPs). For this, we synthesize and characterize nanomicelles, as well as analyze some parameters, such as particle size, radioactivity emission, dynamic light scattering, and microscopic atomic force. [ 223 Ra]Ra nanomicelles co-loaded with [ 198 Au]AuNPs, with simultaneous alpha and beta emission, showed no instability, a mean particle size of 296 nm, and a PDI of 0.201 (±0.096). Furthermore, nanomicelles were tested in an in vitro cytotoxicity assay. We observed a significant increase in tumor cell death using combined alpha and beta therapy in the same formulation, compared with these components used alone. Together, these results show, for the first time, an efficient association between alpha and beta therapies, which could become a promising tool in the control of tumor progression. |
